ATE346931T1 - Clostridium perfringens impfstoff - Google Patents

Clostridium perfringens impfstoff

Info

Publication number
ATE346931T1
ATE346931T1 AT98202032T AT98202032T ATE346931T1 AT E346931 T1 ATE346931 T1 AT E346931T1 AT 98202032 T AT98202032 T AT 98202032T AT 98202032 T AT98202032 T AT 98202032T AT E346931 T1 ATE346931 T1 AT E346931T1
Authority
AT
Austria
Prior art keywords
beta
toxin
relates
clostridium perfringens
toxins
Prior art date
Application number
AT98202032T
Other languages
English (en)
Inventor
Ruud Philip Antoon Mar Sergers
Nicolas Robin Waterfield
Peer Lyng Frandsen
Jeremy Mark Wells
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Application granted granted Critical
Publication of ATE346931T1 publication Critical patent/ATE346931T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT98202032T 1997-06-20 1998-06-17 Clostridium perfringens impfstoff ATE346931T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201888 1997-06-20

Publications (1)

Publication Number Publication Date
ATE346931T1 true ATE346931T1 (de) 2006-12-15

Family

ID=8228464

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98202032T ATE346931T1 (de) 1997-06-20 1998-06-17 Clostridium perfringens impfstoff

Country Status (17)

Country Link
US (1) US6610300B1 (de)
EP (1) EP0892054B1 (de)
JP (1) JP4234232B2 (de)
KR (1) KR19990007306A (de)
CN (2) CN101914145A (de)
AT (1) ATE346931T1 (de)
AU (1) AU743498B2 (de)
BR (1) BR9802361A (de)
CA (1) CA2235445A1 (de)
DE (1) DE69836520T2 (de)
DK (1) DK0892054T3 (de)
ES (1) ES2276448T3 (de)
HU (1) HUP9801384A3 (de)
NZ (1) NZ330749A (de)
PT (1) PT892054E (de)
TW (1) TWI221847B (de)
ZA (1) ZA985393B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
FR2768747B1 (fr) * 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
RU2409385C2 (ru) 2006-03-30 2011-01-20 Эмбрекс, Инк. Способ иммунизации птицы против инфекции, вызванной бактериями clostridium
KR20080110908A (ko) * 2006-04-17 2008-12-19 쉐링-프라우 리미티드 재조합의 약독화된 클로스트리듐 유기체 및 백신
US20100062025A1 (en) * 2006-11-20 2010-03-11 Intervet International B.V. Use of Clostridium perfringens type C bacterium for the manufacture of a vaccine
EP3351268B1 (de) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Behandlung von immunerkrankungen durch mukosale abgabe von antigenen
BRPI0812346B1 (pt) * 2007-06-08 2019-01-22 Australian Poultry Crc Pty Ltd célula hospedeira, método para a produção de um polipeptídeo isolado, composição, vacinas, método de atenuação da virulência de uma bactéria, método para determinar se um indivíduo foi exposto a um patógeno e uso da célula hospedeira, das vacinas ou da bactéria
EP2198007B1 (de) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmazeutische zusammensetzungen mit clostridium difficile toxoiden a und b
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN110882384B (zh) * 2019-12-17 2024-01-26 天康生物制药有限公司 猪流行性腹泻-猪梭菌性肠炎二联亚单位的口服疫苗及制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN118955663A (zh) * 2024-08-30 2024-11-15 中国兽医药品监察所 一株产气荚膜梭菌cpb单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB958574A (en) * 1959-11-23 1964-05-21 Wellcome Found Clostridium perfringens ª‰-toxoid vaccines
SE7809880L (sv) * 1978-09-20 1980-03-21 Zemlyakova Valentina Porfiriev Vaccin for profylax och behandling av clostridiosis hos djur och fjederfe
WO1993023543A1 (en) * 1992-05-20 1993-11-25 The Secretary Of State For Defence Of The United Kingdom Of Great Britain And Northern Ireland Clostridium perfringens vaccines
US5538851A (en) * 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
GB9522611D0 (en) 1995-11-03 1996-01-03 Brooks Holdings Ltd Improvements in and relating to a security closure for a door opening
GB9605222D0 (en) * 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines

Also Published As

Publication number Publication date
HU9801384D0 (en) 1998-08-28
CN1215729A (zh) 1999-05-05
US6610300B1 (en) 2003-08-26
HUP9801384A3 (en) 2001-11-28
KR19990007306A (ko) 1999-01-25
JPH11103872A (ja) 1999-04-20
DK0892054T3 (da) 2007-04-02
AU743498B2 (en) 2002-01-24
EP0892054B1 (de) 2006-11-29
ES2276448T3 (es) 2007-06-16
BR9802361A (pt) 2000-01-11
JP4234232B2 (ja) 2009-03-04
CA2235445A1 (en) 1998-12-20
CN101914145A (zh) 2010-12-15
TWI221847B (en) 2004-10-11
HUP9801384A2 (hu) 1999-03-29
ZA985393B (en) 1999-02-17
DE69836520D1 (de) 2007-01-11
EP0892054A1 (de) 1999-01-20
PT892054E (pt) 2007-02-28
NZ330749A (en) 1999-10-28
DE69836520T2 (de) 2007-06-06
AU7308798A (en) 1998-12-24

Similar Documents

Publication Publication Date Title
DK0892054T3 (da) Clostridium perfringens-vaccine
BR9906927A (pt) Proteìnas de neisseria meningitidis
NZ540544A (en) Nucleic acids and proteins from streptococcus groups A & B
EP1203817A3 (de) Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
ATE229978T1 (de) Helicobacter proteine und impstoffe
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU2785089A (en) Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
MX9708426A (es) Polipeptido hk2 de variante estable.
IL125797A0 (en) Parapoxviruses which contain foreign dna their preparation and their use in vaccines
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
AU5554301A (en) Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
AU3172095A (en) Coccidiosis poultry vaccine
AU3711597A (en) A novel galanin receptor
DK0941241T3 (da) Bordetella-stamme, som udtrykker hybridet FHA
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
WO1999015669A3 (fr) Toxine de clostridium, et procede de preparation de compositions immunogenes
NO20005482L (no) Rekombinant virus og anvendelser derav samt vaksine som omfatter nevnte virus.
WO2001076622A3 (en) Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof
NZ334582A (en) Polyprotein construct of a papillomavirus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0892054

Country of ref document: EP

REN Ceased due to non-payment of the annual fee